Lifesci Capital Comments on Kodiak Sciences Q3 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities research analysts at Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for shares of Kodiak Sciences in a note issued to investors on Thursday, October 23rd. Lifesci Capital analyst P. Dolezal anticipates that the company will post earnings per share of ($1.09) for the quarter. Lifesci Capital has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. Lifesci Capital also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.47) EPS, FY2026 earnings at ($3.09) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($2.68) EPS and FY2029 earnings at ($1.61) EPS.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.02).

Several other analysts have also recently commented on the company. JPMorgan Chase & Co. upgraded Kodiak Sciences from a “neutral” rating to an “overweight” rating and upped their target price for the company from $15.00 to $24.00 in a report on Friday. Wall Street Zen downgraded Kodiak Sciences from a “hold” rating to a “sell” rating in a report on Saturday, October 11th. HC Wainwright increased their price target on Kodiak Sciences from $3.00 to $5.00 and gave the stock a “neutral” rating in a report on Monday, August 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a report on Wednesday, October 8th. Finally, Chardan Capital reiterated a “neutral” rating and set a $14.00 price target on shares of Kodiak Sciences in a report on Monday, October 6th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $19.17.

Kodiak Sciences Price Performance

Shares of KOD stock opened at $18.83 on Monday. The business’s 50 day simple moving average is $12.50 and its 200 day simple moving average is $7.47. Kodiak Sciences has a one year low of $1.92 and a one year high of $20.13. The stock has a market capitalization of $994.60 million, a PE ratio of -4.96 and a beta of 2.67.

Hedge Funds Weigh In On Kodiak Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in KOD. Vontobel Holding Ltd. bought a new position in shares of Kodiak Sciences during the 1st quarter worth about $28,000. Federated Hermes Inc. bought a new position in shares of Kodiak Sciences during the 1st quarter worth about $236,000. GSA Capital Partners LLP boosted its position in shares of Kodiak Sciences by 163.6% during the 1st quarter. GSA Capital Partners LLP now owns 205,833 shares of the company’s stock worth $577,000 after purchasing an additional 127,748 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Kodiak Sciences during the 1st quarter worth about $126,000. Finally, US Bancorp DE boosted its position in shares of Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after purchasing an additional 5,276 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.